Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
Keywords: Coronary artery disease, gastrointestinal inflammation, inflammatory bowel disease, microbiota, trimethylamine N-oxide.
Current Drug Targets
Title:Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Volume: 16 Issue: 3
Author(s): Mohammad Bashashati, Hamid R. Habibi, Ali Keshavarzian, Max Schmulson and Keith A. Sharkey
Affiliation:
Keywords: Coronary artery disease, gastrointestinal inflammation, inflammatory bowel disease, microbiota, trimethylamine N-oxide.
Abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
Export Options
About this article
Cite this article as:
Bashashati Mohammad, Habibi R. Hamid, Keshavarzian Ali, Schmulson Max and A. Sharkey Keith, Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150120104012
DOI https://dx.doi.org/10.2174/1389450116666150120104012 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Current Pharmaceutical Design Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Autoimmune Neuromuscular Disorders
Current Neuropharmacology Impaired Clearance of Neutrophils Extracellular Trap (NET) May Induce Detrimental Tissular Effect
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Skin Prick Test with Self-Saliva in Patients with Oral Aphthoses: A New Diagnostic Pathergy for Behcets Disease and Recurrent Aphthosis
Inflammation & Allergy - Drug Targets (Discontinued) Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) VDAC-Targeted Drugs Affecting Cytoprotection and Mitochondrial Physiology in Cerebrovascular and Cardiovascular Diseases
Current Medicinal Chemistry The Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Current Neurovascular Research Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Gene Elements that Regulate Streptococcus pneumoniae Virulence and Immunity Evasion
Current Gene Therapy The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Subject Index To Volume 2
Current Rheumatology Reviews Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Randomized Controlled Trials in Steroid Dependent and in Severe Colitis
Reviews on Recent Clinical Trials Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer
Current Gene Therapy The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry